These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

960 related items for PubMed ID: 15349707

  • 1. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K, Lind T, Wilder-Smith C.
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [Abstract] [Full Text] [Related]

  • 2. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P, Katz PO, Chen Y, Sostek M.
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [Abstract] [Full Text] [Related]

  • 3. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.
    Wilder-Smith CH, Röhss K, Nilsson-Pieschl C, Junghard O, Nyman L.
    Digestion; 2003 Dec; 68(4):184-8. PubMed ID: 14691345
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
    Çelebi A, Aydın D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S.
    Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D, Bagin R, Goldlust B, Major J, Hepburn B.
    Aliment Pharmacol Ther; 2005 Jun 15; 21(12):1467-74. PubMed ID: 15948814
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
    Katz PO, Koch FK, Ballard ED, Bagin RG, Gautille TC, Checani GC, Hogan DL, Pratha VS.
    Aliment Pharmacol Ther; 2007 Jan 15; 25(2):197-205. PubMed ID: 17229243
    [Abstract] [Full Text] [Related]

  • 7. [All proton pump inhibitors are equally efficacious in standard dosages].
    Hellström PM, Vitols S.
    Lakartidningen; 2003 Jun 19; 100(25):2212-6. PubMed ID: 12872509
    [Abstract] [Full Text] [Related]

  • 8. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
    Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL.
    Aliment Pharmacol Ther; 2003 Jun 15; 17(12):1507-14. PubMed ID: 12823153
    [Abstract] [Full Text] [Related]

  • 9. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
    Johnson DA, Stacy T, Ryan M, Wootton T, Willis J, Hornbuckle K, Brooks W, Doviak M.
    Aliment Pharmacol Ther; 2005 Jul 15; 22(2):129-34. PubMed ID: 16011671
    [Abstract] [Full Text] [Related]

  • 10. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ, Salas M, Ward A.
    Clin Ther; 2001 Jul 15; 23(7):998-1017. PubMed ID: 11519776
    [Abstract] [Full Text] [Related]

  • 11. Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole.
    Morgan D, Pandolfino J, Katz PO, Goldstein JL, Barker PN, Illueca M.
    Aliment Pharmacol Ther; 2010 Jul 15; 32(2):200-8. PubMed ID: 20456300
    [Abstract] [Full Text] [Related]

  • 12. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
    Frazzoni M, De Micheli E, Grisendi A, Savarino V.
    Aliment Pharmacol Ther; 2003 Jan 15; 17(2):235-41. PubMed ID: 12534408
    [Abstract] [Full Text] [Related]

  • 13. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T.
    Aliment Pharmacol Ther; 2013 Nov 15; 38(9):1129-37. PubMed ID: 24099474
    [Abstract] [Full Text] [Related]

  • 14. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S.
    Clin Pharmacol Ther; 2006 Jan 15; 79(1):144-52. PubMed ID: 16413249
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
    Remák E, Brown RE, Yuen C, Robinson A.
    Curr Med Res Opin; 2005 Oct 15; 21(10):1505-17. PubMed ID: 16238890
    [Abstract] [Full Text] [Related]

  • 16. Esomeprazole 20mg provides more effective intragastric Acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers.
    Röhss K, Wilder-Smith C, Nauclér E, Jansson L.
    Clin Drug Investig; 2004 Oct 15; 24(1):1-7. PubMed ID: 17516685
    [Abstract] [Full Text] [Related]

  • 17. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.
    Miehlke S, Madisch A, Kirsch C, Lindner F, Kuhlisch E, Laass M, Knoth H, Morgner A, Labenz J.
    Aliment Pharmacol Ther; 2005 Apr 15; 21(8):963-7. PubMed ID: 15813831
    [Abstract] [Full Text] [Related]

  • 18. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ, Andersson TB, Ahlström M, Weidolf L.
    Drug Metab Dispos; 2004 Aug 15; 32(8):821-7. PubMed ID: 15258107
    [Abstract] [Full Text] [Related]

  • 19. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
    Freston J, Chiu YL, Pan WJ, Lukasik N, Täubel J.
    Am J Gastroenterol; 2001 Jul 15; 96(7):2058-65. PubMed ID: 11467632
    [Abstract] [Full Text] [Related]

  • 20. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
    Metz DC, Amer F, Hunt B, Vakily M, Kukulka MJ, Samra N.
    Aliment Pharmacol Ther; 2006 Apr 01; 23(7):985-95. PubMed ID: 16573801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.